These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38419812)

  • 21. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
    Zhang R; Hu C; Zhang J; Zhang Y; Yuan L; Yu P; Wang Y; Bao Z; Cao M; Ruan R; Cheng X; Xu Z
    BMC Cancer; 2023 Jan; 23(1):5. PubMed ID: 36597055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
    Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
    Wang D; Zhang G; Peng C; Shi Y; Shi X
    J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
    Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
    Front Oncol; 2021; 11():678315. PubMed ID: 34367964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.
    Sato S; Itamochi H
    Ther Adv Med Oncol; 2014 Nov; 6(6):293-304. PubMed ID: 25364394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
    Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
    Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
    Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
    BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study.
    Huang J; Du D; Chen H; Luo D; Wang Q; Li C; Li Y; Yu Y
    Front Oncol; 2024; 14():1399502. PubMed ID: 38863620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
    Liu X; Zhao Y; Jiao X; Yu Y; Li R; Zeng S; Chi J; Ma G; Huo Y; Li M; Peng Z; Liu J; Zhou Q; Zou D; Wang L; Li Q; Wang J; Yao S; Chen Y; Ma D; Hu T; Gao Q
    J Ovarian Res; 2023 Jun; 16(1):121. PubMed ID: 37370087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of Prognostic Markers {CEA, Ca19.9, Neutrophil To Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)} With Progression Free Survival (PFS) in Advanced/Metastatic Gallbladder Carcinoma.
    Naik MD; Kataria SP; Kumar G; Singh R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.
    Plaja A; Teruel I; Ochoa-de-Olza M; Cucurull M; Arroyo ÁJ; Pardo B; Ortiz I; Gil-Martin M; Piulats JM; Pla H; Fina C; Carbó A; Barretina-Ginesta MP; Martínez-Román S; Carballas E; González A; Esteve A; Romeo M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
    Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation.
    Cho JH; Kim S; Song YS
    Chin Clin Oncol; 2018 Dec; 7(6):58. PubMed ID: 30509079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey.
    Acikgoz O; Yildiz A; Bilici A; Olmez OF; Basim P; Cakir A
    Anticancer Drugs; 2022 Nov; 33(10):1150-1155. PubMed ID: 36206103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.